---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-010438"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2023-03-31T23:59:59+00:00"
generated_at: "2026-06-17T07:57:33.324116+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Oncocyte reports FY2022 revenue $5.6M (-27%); plans to extend 10-K filing

## Summary
- FY2022 revenue $5.6M (down 27% YoY); Q4 revenue $1.1M (down 69% YoY).
- DetermaRx revenue FY2022 $3.6M (+47% YoY); Q4 $0.8M (+3% YoY).
- Consolidated operating expenses $69.0M including $44.6M impairment loss; continuing ops revenue $1.0M.
- Plans to file Form 12b-25 to extend 10-K deadline to April 17, 2023.
- Cost reduction targets quarterly cash burn below $6M in H2 2023 (from $10.5M in H2 2022).

## SEC filing metadata
- accession: 0001493152-23-010438
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2023-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315223010438/0001493152-23-010438-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315223010438/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-010438
- JSON: https://secwatch.observer/filing/0001493152-23-010438.json
- Plain text: https://secwatch.observer/filing/0001493152-23-010438.txt

## Key facts
- Earnings Releases
  Insight Molecular Diagnostics Inc. reported the full year ended December 31, 2022 results: revenue approximately $1.1 million and $5.6 million, respectively.
  - Period: the full year ended December 31, 2022
  - Revenue: approximately $1.1 million and $5.6 million, respectively
  - Result: preliminary results
  source text: dossier to MolDx in December 2022 2022 Preliminary Financial Results Consolidated revenues for the three and twelve months ended December 31, 2022, were approximately $1.1 million and $5.6 million, respectively, a decrease of 69% compared to fourth quarter 2021 and 27% compared to the full year 2021. Excluding DetermaRx revenue, the continuing
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315223010438/0001493152-23-010438-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.